Print this page
-
A Phase 3, Randomized, Open-Label Study Comparing the Efficacy and Safety of the Combination of Beleodaq-CHOP or Folotyn-COP to the CHOP Regimen Alone in Newly Diagnosed Patients with Peripheral T-Cell Lymphoma
Protocol: 012320Principal Investigator:
- Yun Kyoung Tiger (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
First-in-Human Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of the BTK Degrader, ABBV-101, in
Participants with B-cell Malignancies
Protocol: 012321Principal Investigator:
- Joanna Rhodes MD (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
A Phase 1/2, First in Human Study of DCC-3116 as Monotherapy and in Combination with RAS/MAPK Pathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations
Protocol: 052308Principal Investigator:
- Sanjay Goel (Rutgers University)
Applicable Disease Sites: Any Site -
An Open-label, Multicenter, Phase 2 Dose Optimization and Expansion Study to Evaluate the Safety and Efficacy of BB-1701, an Anti-Human Epidermal Growth Factor Receptor 2 (anti-HER2) Antibody-Drug Conjugate (ADC), in Previously Treated Subjects with HER2-Positive or HER2-Low Unresectable or Metastatic Breast Cancer.
Protocol: 042314Principal Investigator:
- Mridula George (Rutgers University)
Applicable Disease Sites: Breast -
A Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents and Young Adults Receiving Acute Lymphoblastic Leukemia Therapy
Protocol: 112308Principal Investigator:
- Marissa Botwinick MD (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Leukemia, other -
A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB598 Monotherapy and Combination Therapy in Participants with Advanced Malignancies
Protocol: 052310Principal Investigator:
- Sanjay Goel (Rutgers University)
Applicable Disease Sites: Any Site